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The poor prognosis of pancreatic ductal adenocarcinoma (PDAC) is attributed to the highly fibrotic 
stroma and complex multi‑cellular microenvironment that is difficult to fully recapitulate in pre‑
clinical models. To fast‑track translation of therapies and to inform personalised medicine, we 
aimed to develop a whole‑tissue ex vivo explant model that maintains viability, 3D multicellular 
architecture, and microenvironmental cues of human pancreatic tumours. Patient‑derived surgically‑
resected PDAC tissue was cut into 1–2 mm explants and cultured on gelatin sponges for 12 days. 
Immunohistochemistry revealed that human PDAC explants were viable for 12 days and maintained 
their original tumour, stromal and extracellular matrix architecture. As proof‑of‑principle, human 
PDAC explants were treated with Abraxane and we observed different levels of response between 
patients. PDAC explants were also transfected with polymeric nanoparticles + Cy5‑siRNA and we 
observed abundant cytoplasmic distribution of Cy5‑siRNA throughout the PDAC explants. Overall, our 
novel model retains the 3D architecture of human PDAC and has advantages over standard organoids: 
presence of functional multi‑cellular stroma and fibrosis, and no tissue manipulation, digestion, or 
artificial propagation of organoids. This provides unprecedented opportunity to study PDAC biology 
including tumour‑stromal interactions and rapidly assess therapeutic response to drive personalised 
treatment.
Patients with pancreatic ductal adenocarcinoma (PDAC) have less than 9% chance of survival 5 years post-
diagnosis1. Despite aggressive treatment regimes, there has been little improvement in patient survival in the 
past 3  decades2,3. A critical driver of PDAC tumour aggressiveness and a key barrier to drug delivery is the highly 
fibrotic stroma which can make up the majority of the tumour  mass4,5 and is produced by cancer-associated 
fibroblasts (CAFs)6. A PDAC-CAF cell cross-talk network is known to promote the progression, chemoresistance 
and metastasis of pancreatic  tumours6–8. This is also a key limitation to pre-clinical evaluation of therapeutics for 
PDAC, as a majority of pre-clinical in vitro/ex vivo PDAC models lack the presence of CAFs and an abundant 
and functional fibrotic stroma. Thus, in order to fast-track the clinical translation of new drug candidates and to 
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identify existing drugs that will be effective on a patient’s individual tumour, there is an unmet need to develop 
better pre-clinical models that are: (1) easy to establish; (2) cost-effective; (3) provide results in a timely manner 
to inform patient treatment; (4) avoid mechanical or enzymatic digestion of tissue; and (5) closely reflect the 
biology of human disease.
Currently, human-PDAC xenograft mouse models and genetically engineered mouse models (GEMMs) are 
the gold-standard for pre-clinical drug testing and are highly valuable tools to study PDAC  biology9,10. Patient-
derived xenograft mouse models can reflect inter-patient heterogeneity, but are expensive, time consuming, lack 
the presence of a functional immune system, and have the extra complexity of infiltrating mouse stroma into 
a tumour of human  origin11,12. GEMMs contain a complex multicellular fibrotic microenvironment, however 
the species genome is not identical to the human genome and they are expensive and time-consuming9. Recent 
years have seen the development of patient-derived organoid models as a pre-clinical model, but these involve 
the manipulation and mechanical or enzymatic digestion of human tumour tissue and are often derived from a 
single cell type (tumour cells)13,14 which does not fully mimic human PDAC tumours. Most importantly, orga-
noids often lack a fibrotic stroma and the presence of CAFs and blood vessels. Taken together, these limitations 
highlight the need to develop more clinically relevant models of PDAC to complement the other models available.
Recent evidence highlights that the in situ spatial interaction between tumour and stromal cells in PDAC can 
provide clinically-important  information15. Thus, an ideal model should reflect the complex microenvironment 
and contain all cell types within the same 3D architecture as they were present in a patient’s tumour. Here, we 
have developed a new PDAC pre-clinical model that retains the 3D architecture of human patient derived PDAC 
tumours. Importantly, this model does not involve any chemical, enzymatic, or mechanical digestion of PDAC 
tissue and thus avoids artificially skewing cell populations. We further demonstrate that this model can be applied 
to test both clinically approved chemotherapy drugs as well as novel therapeutics including a nano-based gene 
silencing drug developed in our lab. This new model provides a unique opportunity to closely study the biology 
of the PDAC tumour microenvironment, to identify novel gene targets and test new treatment strategies in a 
cost-effective and timely manner.
Results
Culture and characterisation of human patient derived PDAC explants. Human PDAC tumour 
tissue was obtained from patients undergoing surgical resection (pancreaticoduodenectomy) of pancreatic can-
cer. Patient characteristics are listed in Supplementary Table S1 online. A small piece of tissue was resected from 
the tumour mass and transported within 15 min to the laboratory on ice. The tumour tissue was cut into 1–2 mm 
explants and cultured on pre-soaked gelatin sponges for 12 days (Fig. 1a and Supplementary Fig. S1 online). 
Hematoxylin and eosin (H&E) staining revealed that both tumour and stromal architecture of the patient PDAC 
explants was retained throughout the 12-day culture (Fig. 1b and Supplementary Figs. S2-S3 online). With simi-
lar architecture to the uncultured day 0 controls, we observed in cultured PDAC explants an arrangement of 
both cytokeratin-positive tumour cells and stromal αSMA-positive CAFs within an abundant distribution of 
fibrillar collagen (Fig. 2 and Supplementary Figs. S4-S8 online). Importantly, we demonstrated positive staining 
for two independent cell proliferation markers [ki67 and phospho-histone H3 (PHH3)], and negative staining 
for a cell-death marker (TUNEL, Fig. 3 and Supplementary Figs. S4-S8 online). A PDAC explant section treated 
with DNAse served as a positive control for TUNEL (Supplementary Fig. S9 online). To assess the de novo prolif-
eration status of PDAC explants, we treated explants from two PDAC patients with bromodeoxyuridine (BrdU) 
for 24 h prior to fixation at day 12. We observed positive nuclear staining of BrdU in a majority of tumour cells 
and a subset of stromal cells at day 12 (Fig. 4).
We next investigated whether tumour specific drivers are maintained in cultured explants. We performed 
immunohistochemistry to assess p53 protein status in day 0 and day 12 PDAC explants from patients 1–6. All 
patient tumour explants contained positive p53 protein in tumour cells at day 0 and after 12 days of culture 
(Fig. 5).
We also performed immunohistochemistry for CD45 (lymphocyte marker) and observed a high degree of 
lymphocyte infiltrate in the day 0 control explants of patient 3, and this was maintained in explants cultured 
for 5 days (Fig. 6). Interestingly, according to the surgical pathology report of the resected tumour, patient 3 
had a rare loss of MSH6 expression which is known to increase neoantigen presentation and could explain the 
unusually high amount of CD45-positive immune cells in the tumour. In contrast, patient 1 and 2 explants had 
significantly less CD45-positive lymphocytes cells. Notably, the amount of immune infiltrate across all patients 
was maintained between day 0 and day 5 explants. Explants cultured for 7–12 days had very few CD45-positive 
cells (data not shown), suggesting that the lymphocytes present in the patient’s tumours only remain present for 
5 days in our ex vivo explant model.
We also performed light sheet microscopy on day 0 explants from two PDAC patients, demonstrating the 
ability to image a whole tissue explant in 3D. The 3D reconstruction of the day 0 control tissue explant showed 
individual cell nuclei with distinct areas of F-actin (phalloidin) expression throughout the explant (Supplemen-
tary Fig. S10 online). This could suggest a dispersed arrangement of F-actin rich stromal  cells16 throughout the 
tissue. We next proceeded to stain a day 0 explant from another PDAC patient with more specific cell markers 
(cytokeratin and αSMA). As expected, the 3D reconstruction of the whole tissue explant demonstrated distinct 
areas of cytokeratin-positive tumour elements and αSMA-positive CAFs (Supplementary Fig. S10 online).
In addition to patients with PDAC, we also cultured explants from three patients with pancreatic neuroen-
docrine tumours (PNET). H&E staining demonstrated that the architecture of these explants was also main-
tained after 12 days of culture (Supplementary Fig. S11 online). We stained the day 0 and day 12 PNET explants 
with a neuroendocrine specific marker (synaptophysin) and although the number of neuroendocrine cells var-
ied between the 3 patients, this was maintained between day 0 and day 12 explants from the same patients 
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:1944  | https://doi.org/10.1038/s41598-021-81299-0
www.nature.com/scientificreports/
(Supplementary Fig. S11 online). We also cultured tumour explants from a patient with a rare metastasis of a 
leiomyosarcoma to the pancreas, and again H&E staining demonstrated preserved architecture after 12 days of 
culture (Supplementary Fig. S12 online). Overall, these findings show that the ex vivo explant model can main-
tain the viability, cell composition, and extracellular matrix of tissue explants from a range of human pancreatic 
tumours including PDAC and pancreatic neuroendocrine tumours for at least 12 days of culture.
Testing of clinical and novel therapeutics in pancreatic tumour tissue explants. We next inves-
tigated whether the ex vivo explant culture model can be used to test clinically approved or novel therapeutics. 
Figure 1.  Tumour and stromal architecture are maintained in human patient derived pancreatic ductal 
adenocarcinoma explants for 12 days of culture. (a) Schematic showing the set-up of the ex vivo culture method 
and a representative photo of a gelatin sponge containing three PDAC explants in a well of a 24-well plate. White 
arrows point to the three explants on the gelatin sponge during culture. (b) Representative H&E images of 
patient 1 explants at low and high magnification from days 0–12. Tumour elements are outlined in yellow and 
compartments labelled as tumour (T) and stroma (S).
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We first tested Abraxane (human albumin-bound paclitaxel) which is currently one of the chemotherapeutic 
agents used in first-line therapy for  PDAC17. Abraxane (0.3 μg/mL or 4.2 μg/mL) was added to the medium 
reservoir every 3 days and explants were fixed on day 12. We then performed TUNEL staining to assess cell 
death. PDAC explants from 2 patients (patients 2 and 7) were sensitive to Abraxane with high levels of cell death 
following Abraxane treatment (39–63% TUNEL positivity, Fig. 7a,b and Supplementary Fig. S13 online). H&E 
staining revealed architectural changes to tumour cells with Abraxane treatment including fragmentation of 
ductal elements (black arrows, Fig. 7a). In contrast, we identified a PDAC patient (patient 8) whose explants 
were non-responsive to Abraxane with less than 6% TUNEL positivity observed in the Abraxane treated explants 
(Supplementary Fig. S14 online). No clinical treatment information was available for patients 2 and 7, as patient 
2 elected to not receive adjuvant chemotherapy, and patient 7 had not yet begun adjuvant chemotherapy at the 
Figure 2.  Characterisation of human patient derived pancreatic ductal adenocarcinoma explants cultured for 
12 days. Immunohistochemistry was performed for cytokeratin, α-smooth muscle actin (αSMA), and collagen 
(picrosirius red/methyl green) on patient 1 explants from days 0–12.
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time of submission of the manuscript. However, for patient 8, clinical information showed that this patient had 
a Whipple resection prior to the onset of this study (September 2017) for a moderately differentiated adeno-
carcinoma of the head and neck of the pancreas. The patient received Gemcitabine and Abraxane adjuvant 
chemotherapy, but the tumour recurred as a moderately differentiated PDAC in the tail of the pancreas which 
was resected (August 2020), and tumour explants established from this resection.
Another key potential of our novel ex vivo explant model is the ability to perform real-time mechanistic 
studies and study cell–cell interactions in an unmanipulated piece of human PDAC tissue. We hypothesised that 
gene therapeutics such as siRNA would be a useful tool to perform such studies, hence we examined whether 
our tissue explant model is amenable to transfection with nanoparticle-siRNA18,19. A di-block copolymer nano-
particle (Star 3) developed in our  lab18,19 was complexed to fluorescently labelled siRNA. Human PDAC explants 
Figure 3.  Human patient derived pancreatic ductal adenocarcinoma tumour explants remain viable for 12 days 
of culture. Immunohistochemistry was performed for ki67, phospho-histone H3 (PHH3) and TUNEL on 
patient 1 explants from days 0–12. Insets show representative higher magnification views.
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were placed in triplicate on gelatin sponges that had been pre-soaked in medium containing Star 3 complexed to 
siRNA. After 24 h, tissue explants were processed for frozen tissue sections and Star 3-siRNA uptake assessed by 
confocal microscopy. As proof-of-principle, we demonstrated that Star 3-siRNA treated tissue explants had abun-
dant uptake of fluorescent siRNA throughout the tissue explants (Fig. 8a and Supplementary Fig. S15 online). 
Quantification of mean fluorescence from three separate explants from the same patient revealed significantly 
higher levels of uptake in Star 3 + Cy5-siRNA treated explants compared to untreated controls (4.7-fold increase, 
p = 0.0176, n = 3 explants per treatment, Fig. 8b).
Discussion
In this study, we describe the development and characterisation of a novel human pre-clinical model of pan-
creatic ductal adenocarcinoma (PDAC) that maintains the viability, 3D multicellular architecture and micro-
environmental cues of unmanipulated patient derived tumours. This simple and cost-effective model provides 
unprecedented opportunity to closely study the biology of pancreatic cancer, to identify novel gene therapeutic 
Figure 4.  Patient derived pancreatic ductal adenocarcinoma tumour explants demonstrate positive 
bromodeoxyuridine (BrdU) staining after 12 days of culture. Patient 7 and 8 tumour explants were treated with 
10 μM BrdU for 24 h prior to fixation at day 12. Immunohistochemistry demonstrated positive BrdU staining in 
both tumour and stromal cells in the day 12 explants.
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targets for tumour and stromal cells, to test the anti-cancer activity of novel drugs or combination treatments, 
and has potential to inform precision medicine for pancreatic cancer. PDAC urgently requires new and more 
effective treatments. However, for the efficacy of new therapeutic strategies to be evaluated, there is a need for 
robust pre-clinical models that accurately reflect the biology of the disease in patients. Currently, a broad range 
of PDAC models are available; ranging from cell lines, GEMMs, patient derived xenografts, and most recently, 
organoid  cultures9,10,14. There is no perfect model and each model has its strengths and limitations. For example, 
2D in vitro cell line cultures can provide important insights into the signalling pathways dysregulated in cancer 
cells, but they lack the complexity of a 3D tumour mass. Subcutaneous or orthotopic mouse models of PDAC 
have the advantage of a 3D arrangement of cancer cells but are often derived from a single cell type. Patient 
derived xenografts can model interpatient heterogeneity, but are time consuming, expensive, have the complex-
ity of infiltrating mouse stromal cells into a tumour of human origin, and the poor tumour engraftment can 
Figure 5.  Human patient derived pancreatic ductal adenocarcinoma tumour explants maintain p53 protein 
status after 12 days of culture. Immunohistochemistry was performed for p53 on day 0 and day 12 tumour 
explants from patients 1–6. Insets show representative higher magnification views.
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potentially bias more aggressive  disease11. GEMMs have the advantage of spontaneously forming tumours that 
can mimic patient tumourigenicity in an immune proficient setting but are also time consuming, expensive, and 
may not always reflect therapeutic response due to mouse and human species  differences9. Recently, patient-
derived organoids have gained much attention for their ability to rapidly model interpatient heterogeneity, but 
they often consist of tumour cells that have been dissociated from their native extracellular matrix and tumour 
 microenvironment13,14. Additionally, most organoids lack the characteristic fibrotic stroma, which is a key drug 
delivery barrier and is known to drive the progression of  PDAC6–8. With this in mind, we identified that there 
is a significant gap in the pre-clinical models available for PDAC, and in particular, there is a need for a model 
with: (1) abundant and functional stroma, and (2) multicellular architecture with the same 3D organisation as 
present in human disease.
At the onset of this study, we hypothesised that the ex vivo human patient-derived explant model, established 
in prostate and breast cancer, has the potential to overcome many of these  limitations20. This model involves 
the culture of freshly resected tumour tissue explants (around 1–2 mm diameter) on a gelatin sponge support 
scaffold soaked in culture  media20. Nutrients can be taken up by the explants via capillary action through the 
gelatin sponge, preventing the need to submerge the tissue in culture media which often leads to its degradation 
within a few days. This model has been used to culture prostate, breast and ovarian cancer explants, but has yet 
to be translated to  PDAC20–24.
Recently, a study by Misra et al. (2019)25 cultured 350 μm thick PDAC tumour tissue-slices on a cell-culture 
Millicell insert for up to 96 h. While this was the first study to culture whole-tissue slices of PDAC and represents 
significant progress in developing more clinically relevant models of PDAC, the culture was only maintained 
for 96 h and low levels of tissue death were observed from as early as 24 h of  culture25. A follow up study dem-
onstrated that these cultured PDAC tissue slices have genomic stability with minimal transcriptome changes 
throughout the 72 h of  culture26. Several other studies have developed in vitro co-culture models containing 
tumour cells, cancer-associated fibroblasts (CAFs), and endothelial  cells27–31, but these models do not perfectly 
mimic the in situ complexity and heterogeneity of human PDAC tumours. For example, an impressive study by 
Gupta et al.27 developed a co-culture model of cancer cells, endothelial cells and CAFs on a polyurethane scaffold. 
While such models can be useful for high-throughput screening of therapeutics, they consist of cells artificially 
dissociated from their native architecture and microenvironment which may not represent the complexity of 
human disease.
Here, we report for the first time that the gelatin sponge ex vivo explant culture method can be used to cul-
ture human patient derived PDAC whole-tissue tumour explants for up to 12 days. We cultured human PDAC 
explants derived from patient tumours immediately following surgical resection of the tumour. Remarkably, 
both the tumour and stromal architecture of the explants were retained throughout the 12-day culture, and this 
was reproduced across six PDAC patients. Indeed, the tissue explants showed dispersed cytokeratin-positive 
tumour elements surrounded by a dense arrangement of αSMA-positive CAFs and an abundant network of 
fibrillar collagen, which was highly comparable from days 0–12. Using multiple orthogonal approaches, we 
comprehensively demonstrated that the proliferative status of both tumour cells and stromal cells is maintained 
throughout the 12 days culture. We highlighted this by observing positive staining for ki67 and phosphorylated-
histone H3 (marker of mitotically active  cells32–34), as well as bromodeoxyuridine DNA incorporation providing 
strong evidence that cells display de novo cell proliferation after 12 days of culture.
Immunohistochemistry also revealed that p53 protein status in tumour cells is maintained between day 0 
and day 12 explants. Immunohistochemistry has been used to assess p53 status in PDAC and other cancers, 
as the mutated form of p53 protein is known to accumulate in the nucleus of tumour cells and is detectable by 
immunohistochemistry, whereas the wild-type protein is rapidly  degraded36–39. Thus, by demonstrating positive 
Figure 6.  CD45-positive lymphocytes remain viable for 5 days in human patient derived pancreatic ductal 
adenocarcinoma tumour explants. Immunohistochemistry was performed for lymphocyte marker CD45 on 
tumour explants from patients 1–3 at day 0 and day 5.
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p53 staining in tumour cells between day 0 and day 12 PDAC explants, and consistent with previous findings in 
ex vivo cultured PDAC  slices26, our results suggest that tumour specific drivers such as p53 (which is mutated 
in approximately 75% of PDAC  patients40,41) are maintained in our PDAC explant model. Future studies will 
be required to examine the presence of other established PDAC tumour genetic drivers in our explant model.
Figure 7.  Testing of clinical therapeutics in human patient derived pancreatic ductal adenocarcinoma explants. 
(a) Tumour explants from patient 2 were treated with or without 0.3 μg/mL Abraxane on days 0, 3, 6 and 9, 
then fixed on day 12. TUNEL staining was performed to assess levels of cell death. Black arrows in H&E stained 
sections point to areas of ductal fragmentation in Abraxane treated explants. (b) Quantification of TUNEL 
positive cells using QuPath demonstrated increased cell death in Abraxane treated explants compared to 
untreated controls. A paired t-test was performed to compare TUNEL-positivity in control vs Abraxane treated 
explants from a single patient, with 3–4 explants per treatment from distinct regions of the patient’s tumour 
(represented by each dot in the bar graph). Bars represent mean ± S.E.M., *p = 0.0306.
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While PDAC is generally characterised by an immunosuppressive microenvironment with limited intra-
tumoural immune cell populations, we cultured explants from a patient with a rare loss of MSH6 expression 
(patient 3) where we observed a prominent infiltrate of CD45-positive lymphocytes. Loss of MSH6 results in a 
deficiency in mismatch repair which can increase neoantigen presentation on tumour cells and promote T-cell 
 infiltration42. Notably, this immune population was maintained up to 5 days of culture, thus providing a window 
to potentially study the effects of immunotherapy on a 3D culture of human PDAC tissue. There is also potential 
to add patient autologous immune cells to the explant culture and study how they interact with different cell 
types and the effects of stromal remodelling on immune cell activity and invasion.
Figure 8.  Biodistribution of Star 3 nanoparticles in human patient derived pancreatic ductal adenocarcinoma 
explants. (a) Patient-derived explants from patient 13 were treated for 24 h with or without Star 3 polymeric 
nanoparticles coupled to Cy5-siRNA. Representative images show uptake of Cy5-siRNA throughout the entire 
explants. (b) Quantification of Cy5 mean fluorescence demonstrated significant uptake of Star 3 + Cy5-siRNA in 
treated explants compared to untreated controls. A paired t-test was performed to compare mean fluorescence 
normalised to explant area from a single patient, with 3 explants per treatment from distinct regions of the 
patient’s tumour (represented by each dot in the bar graph). Bars represent mean ± S.E.M., *p = 0.0176.
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Taken together, by highlighting that the overall pathology, viability, 3D multicellular architecture and genetic 
drivers are maintained in our PDAC tumour explant model, we demonstrate that there is no drift in the pheno-
type or genotype of the tumour explants over time. This is an advantage over patient derived xenograft models 
which have been shown to lose human stroma and replace it with mouse  stroma12. Our results also highlight 
the low likelihood of dramatic cellular changes occurring within the cultured PDAC explants. While there may 
be subsets of cells that undergo senescence or cell-cycle changes within the explants, we expect them to be in 
a similar fraction of cells at baseline in the original patient’s tumour and as known to occur in human PDAC 
tumours in situ35.
Interestingly, we also demonstrated that our model can be used to culture pancreatic neuroendocrine tumour 
explants as well as tissue explants derived from a patient with metastatic leiomyosarcoma to the pancreas, provid-
ing an opportunity to study other pancreatic malignancies which also have poor patient outcome.
The ability to maintain the viability of a patient’s tumour in the lab over a 12-day window is a major advance-
ment and has the potential to revolutionise pancreatic cancer research. Firstly, this model provides an unprec-
edented opportunity to perform real-time mechanistic studies to better understand interactions of tumour cells 
with their surrounding stromal and immune cell populations in the same native 3D architecture as they were 
present in a patient’s tumour. We also propose that the ex vivo tissue explant model can become an integral 
component of the drug development pipeline as it allows for the potential of new drugs to be evaluated within 
the context of the major cell types present in an individual patient’s tumour. Inter-patient heterogeneity can be 
recapitulated in the explant model, allowing the applicability of a new drug to be assessed and to inform which 
patients would likely benefit from a proposed new treatment. Live tracking of treatment response could also be 
possible by sampling the medium reservoir and analysing secreted factors related to cell death and senescence 
as a measure of treatment response.
We investigated whether our tissue explant model is amenable to transfection with nano-based gene silenc-
ing drugs. We showed that polymeric nanoparticles which can deliver siRNA to PDAC cells both in vitro and 
in vivo18,19, delivered siRNA throughout the human PDAC tumour explants. No obvious toxicity from the 
nanoparticle treatment was observed. Thus, the potential to administer therapeutics to patient-derived explants 
in this model may provide an opportunity to evaluate a novel therapeutic agent before using expensive and time-
consuming mouse models. From a nanomedicine perspective, this model holds potential to test the interaction of 
nanoparticles with all cell types present in a tumour, and to observe their biodistribution in a clinically relevant 
3D piece of human tumour tissue. This information is critical, especially in PDAC, to facilitate the translation 
of nanomedicines to the  clinic43. In addition, the potential to transfect patient derived human PDAC tumour 
explants with siRNA or other gene modifying agents (e.g. miRNA mimics/inhibitors, DNA or CRISPR/Cas) 
provides an opportunity to perform real-time mechanistic studies in tumour tissue containing a 3D multicellular 
architecture and complex microenvironment.
Most importantly, the PDAC explant model has potential to inform a personalised medicine program for 
PDAC. Patient-derived xenograft models are being investigated as a tool to guide personalised medicine in other 
cancer  types44, but the length of time required to establish these models makes them unsuitable for cancers such 
as PDAC that have such poor survival. Recent years have seen the focus shift to organoid cultures to inform 
individual patient  treatment13,45–49, but a limitation of most organoid models is that they lack the presence of 
stroma—a major drug delivery barrier for PDAC. While organoids may reflect tumour cell intrinsic resistance 
to a given chemotherapy agent, a patient’s tumour cells deemed to be “sensitive” to a chemotherapeutic may in 
fact be resistant in the presence of a fibrotic stroma containing CAFs and immune cells that are well known to 
cross-talk with tumour cells to promote chemoresistance.
As a proof-of-principle, we demonstrated that patient-derived tissue explants can be treated with Abraxane 
and anti-cancer activity measured by TUNEL staining as a readout for cell-death. We performed Abraxane 
treatment in explants from three PDAC patients, two of which showed clear sensitivity to Abraxane whereas the 
third patient’s explants were non-responsive to Abraxane. Intriguingly, the patient whose explants were non-
responsive to Abraxane had recurrence of PDAC following Gemcitabine and Abraxane adjuvant chemotherapy. 
This suggests that the patient’s tumour was not responsive to Abraxane which was successfully recapitulated in 
our tumour explant model. Future studies will assess the ability of our explant model to predict patient response 
to drug treatments in the clinic and to inform personalised therapies for PDAC.
Importantly, this model is both cost effective and time efficient. Preparation of the explants can be completed 
in approximately 30 min after receiving the surgical sample, so a team of two researchers could process explants 
from multiple patients within a given week. In our experience, we were able to obtain at least 30 explants from 
each patient which could allow around 10 different treatment groups to be established from each patient with 
three explants per treatment group to ensure tumour heterogeneity is reflected.
In addition to informing precision medicine, our PDAC tumour explant model may also provide insight into 
how chemotherapy treatment affects the microenvironment of PDAC tumours. This has been studied using the 
same model in human prostate cancer explants and revealed patient-specific changes to the stroma and microen-
vironment following chemotherapy  treatment50. Another potential of the PDAC explant model is the opportunity 
to investigate stromal reprogramming agents by evaluating the effects on CAFs and the extracellular matrix in a 
model that uniquely maintains the tumour and stromal architecture of patient derived tissue.
While the pancreatic tumour explant model established in this study holds promise for PDAC research, a 
limitation is that we have only collected tumour samples from patients with surgically resectable disease which 
represents approximately 15–20% of all PDAC patients and these patients have a better prognosis compared to 
those with unresectable  PDAC2,41. Future studies should focus on developing and strengthening collaborations 
between scientists and clinicians with the aim to obtain fresh tumour tissue from unresectable patients through 
biopsy of their primary tumour and/or metastatic tumours.
12
Vol:.(1234567890)
Scientific Reports |         (2021) 11:1944  | https://doi.org/10.1038/s41598-021-81299-0
www.nature.com/scientificreports/
Nonetheless, this study has established a promising new pre-clinical model of PDAC that retains the native 3D 
multicellular architecture of human pancreatic tumours over 12 days of culture. While we do not believe that this 
model replaces the need for mouse models, we propose that the ex vivo tissue explant model is a clinically relevant 
complement to currently available pre-clinical models. Importantly, the ex vivo tissue explant culture method can 
answer fundamental biological questions and has potential to guide a precision medicine program for PDAC.
Material and methods
Ex vivo explant culture. Prior to collection of tumour tissue, haemostatic gelatin sponges (Johnson & 
Johnson, Cat. JJ-12505) were briefly submerged in culture medium containing high-glucose DMEM, 10% FBS, 
5 mM GlutaMAX, 0.01 mg/mL hydrocortisone, 0.01 mg/mL insulin and 1 × antibiotic/antimycotic solution (all 
from Sigma-Aldrich). Once sponges were soaked, they were placed in 24-well plates and 500 μL culture medium 
was added to each well to cover the bottom-half of each sponge and stored in a 37 °C/5%  CO2 incubator until 
required.
De-identified tumour samples were obtained from patients undergoing a pancreaticoduodenectomy (Whipple 
procedure) at Prince of Wales Hospital or Prince of Wales Private Hospital, Randwick, NSW, Australia. Patients 
provided informed consent through the Health Science Alliance Biobank, all work was approved by UNSW 
human ethics (HC180973) and all experiments were performed in accordance with the relevant guidelines 
and regulations. Tumour tissue was immediately placed in ice-cold PBS containing 1 × antibiotic/antimycotic 
solution and transported on ice. Regions of normal pancreas or fat tissue were dissected away from the tumour 
sample. The remaining tumour tissue was cut into 3 pieces of equal size. The 3 pieces were placed in separate petri 
dishes labelled as “L”, “M”, or “R”. Each of these 3 pieces were then cut using a scalpel into explants with diameter 
ranging from 1–2 mm. Explants from the “L” piece were all placed on the bottom left corner of each pre-soaked 
gelatin sponge, explants from the “M” piece placed in the middle region, and explants from the “R” piece placed 
in the bottom right corner as described in Supplementary Fig. S1 online. This ensured that each gelatin sponge 
contained explants from three distinct regions of the tumour tissue to account for intratumoural heterogeneity. 
A single explant from each of the “L”, “M”, and “R” pieces was immediately fixed in 4% paraformaldehyde and was 
designated the day 0 control. Once all explants had been placed on the sponges, the 24-well plate was placed in a 
37 °C 5%  CO2 incubator. Approximately 30–50 explants could be obtained from each patient. Culture medium 
was replaced daily, with fresh insulin, hydrocortisone and antibiotic/antimycotic solution added to the medium 
immediately prior to it being added to the culture plate. Cultured explants were fixed in 4% paraformaldehyde 
on days 5, 7, 9 and 12 post-establishment of the model for patients 1–3 and on day 12 for patients 4–12. Fixed 
explants were embedded in paraffin and 5 μm slices were prepared at the Histopathology Service at the Garvan 
Institute of Medical Research. All explants were stained with Haematoxylin and Eosin (H&E) for visualisation 
of explant architecture.
Patient derived explants were treated with or without Abraxane (Specialised Therapeutics Australia; 0.3 or 
4.2 μg/mL) by adding Abraxane to the medium used to pre-soak the gelatin sponges on day 0, and 500 μL medium 
containing Abraxane was added to each well. Abraxane treatment was repeated on days 3, 6 and 9. The 0.3 μg/mL 
dose of Abraxane was chosen to match concentrations used in vitro. The 4.2 μg/mL dose of Abraxane was based 
on the maximum plasma concentration of Abraxane after a 30-min intravenous infusion at a dose of 100 mg/
m2 in human clinical pharmacokinetic  data51. To assess BrdU DNA incorporation, explants were treated with 
10 μM BrdU substrate (BD Biosciences, Cat. 550891) for 24 h prior to fixation on day 12.
Immunohistochemistry of patient‑derived pancreatic tumour explants. Patient-derived explant 
tissue sections were stained for cytokeratin (DAKO, Cat. M3515; 1:100 overnight at 4 °C), α-smooth muscle 
actin (αSMA) (Sigma-Aldrich, Cat. A5228; 1:1000 1-h at room temperature), phospho-histone H3 (PHH3) (Cell 
Signalling, Cat. 53348; 1:200 overnight at 4 °C), bromodeoxyuridine (BrdU) (DAKO, Cat. M0744; 1:50 dilution 
overnight at 4 °C), CD45 (ThermoFisher Scientific, Cat. 14-9457-82; 1:100 overnight at 4 °C), or synaptophysin 
(DAKO, Cat. A0010; 1:100 overnight at 4 °C). Briefly, tissue sections were deparaffinised at 60 °C for 30 min 
then rehydrated through consecutive washes in xylene, ethanol, and water. Antigen retrieval was performed by 
microwaving slides for 4 min in 10 mM citrate buffer + 0.05% Tween-20 at pH6.0, followed by a 30-min incu-
bation at 104 °C. Non-specific peroxidase activity was blocked with 1% hydrogen peroxide + 1% methanol for 
10 min at room temperature. For PHH3 and BrdU staining, tissue sections were permeabilised in 0.5% triton 
X-100 (Sigma-Aldrich) for 15 min. An additional DNA hydrolysis step was performed for BrdU staining by 
incubating sections in 3 U/mL DNAse1 for 1 h at 37 °C prior to blocking. After blocking in 10% goat serum, 
tissue samples were stained with primary antibodies as indicated above and isotype control antibodies (mouse 
IgG2A, mouse IgG1A, and rabbit IgG) were used as negative controls (representative images shown in Supple-
mentary Fig. S9 online). Biotinylated anti-rabbit (Vector laboratories, Cat. BA-1000) or anti-mouse (DAKO, Cat. 
E0433) secondary antibodies (1:100) were followed by incubation with Vectastain ABC kit (Vector laboratories). 
3,3′ diaminobenxidine (DAB) was used as the substrate, and tissues were counterstained with hematoxylin. Ki67 
(ThermoFisher Scientific, Cat. RM-9106; 1:1000 dilution) and p53 (Merck Millipore, Cat. OP03; 1:100 dilution) 
staining was performed on a LeicaBond RX Autostainer using a Leica Bond Polymer Refined Detection kit. 
Antigen retrieval was performed using the Leica Bond Epitope Retrieval ER2 at 100 °C for 30 min. All stained 
tissue sections were scanned on an AperioXT (Leica Biosystems) or Vectra Polaris (PerkinElmer) slide scanner.
TUNEL staining was performed according to manufacturer’s instructions (Sigma-Aldrich, Cat. 11684809910). 
Antigen retrieval was performed with 20 μg/mL proteinase K for 15 min at 37 °C. Positive control slides were 
treated with 3 U/mL DNase1 (New England Biolabs, Cat. M0303) for 10 min at room temperature. Tissue sec-
tions were incubated for 1 h at 37 °C with TUNEL enzyme diluted 1:2 in TUNEL dilution buffer. For assessment 
of TUNEL fluorescence (as performed for Abraxane treatment experiment), tissue sections were mounted with 
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ProLong Gold antifade mounting medium with DAPI (Invitrogen, Cat. P36931) and fluorescence scanned on 
a Vectra Polaris (PerkinElmer) slide scanner. QuPath software was used to quantify the amount of TUNEL-
positivity in the whole-tissue explants as a percentage of DAPI-positive cells. A paired t-test (GraphPad Prism 
8) was performed to compare TUNEL-positivity in control vs Abraxane treated explants from a single patient, 
with 3–4 explants per treatment from distinct regions of the patient’s tumour. For the remainder of tissue sec-
tions, TUNEL staining was followed by a 30-min incubation with alkaline phosphatase converter for 30 min at 
37 °C. Fast Red (Acam, Cat. ab64254) was used as the substrate, and tissue sections were counterstained with 
haematoxylin.
Picrosirius red staining of collagen. Patient-derived explant tissue sections were stained with 0.1% pic-
rosirius red for fibrillar collagen and counterstained with methyl green through the UNSW Mark Wainwright 
Analytical Centre Biomedical Imaging Facility (UNSW Sydney).
Uptake of polymeric nanoparticle‑siRNA complexes in human patient derived PDAC tumour 
explants. Polymeric nanoparticles (Star 3) were synthesised as previously  described19. Star 3 nanoparticles 
(62.5 μg) were complexed for 5 min with 25 μg Cy5-labelled siRNA (Dharmacon custom Luc2 siRNA; Cy5-GCU 
UAG GCU GAA UAC AAA UUUU). The complexed Star 3 + Cy5-siRNA was added to the medium used to soak 
the gelatin sponges immediately prior to addition of the explants to the sponges and 500 μL of medium contain-
ing Star 3 + Cy5-siRNA was then added to each well. After 24 h, explants were embedded and frozen in Tis-
sue-Tek Optimal Cutting Temperature Compound (OCT; VWR International). OCT-embedded Sects. (10 μm 
thick) were mounted with ProLong Gold antifade mounting medium with DAPI (Invitrogen, Cat. P36931). 
Fluorescent siRNA uptake was visualised on a Zeiss 900 confocal microscope by taking at least 3 representative 
images from each explant. Whole-tissue explants were scanned on a Vectra Polaris (PerkinElmer) slide scanner. 
Quantification was performed on ImageJ by quantifying the mean fluorescence normalised to explant area of the 
scanned whole-tissue explants. A paired t-test (GraphPad Prism 8) was performed to compare fluorescence of 
Star 3 + Cy5-siRNA treated explants with untreated explants from a single patient, with 3 explants per treatment 
from distinct regions of the patient’s tumour.
Light‑sheet microscopy. Fixed human PDAC explants were embedded in agarose and de-lipidation and 
optical clearing of the explants was performed as previously  described52. Optically cleared samples were then 
stained with AlexaFluor-647-conjugated F-actin antibody (1:200, ThermoFisher) and Hoechst (1:300,Ther-
moFisher) or Cy3-conjugated αSMA antibody (1:400, Sigma-Aldrich) and AlexaFluor-488-conjugated cytoker-
atin antibody (1:400, BioLegend) in PBS for 7 days at 37  °C. The samples were then equilibrated in reagent 
2 [50wt% sucrose, 25wt% urea, 10wt% 2,2,2′-nitrilotriethanol and 0.1% (v/v) Triton X-100] for 2 days52. The 
stained explants were imaged on a Zeiss Light-sheet Z.1 light-sheet microscope. The imaging was performed 
with a 5 × /0.16 detection lens and two light-sheet illuminations (left and right) using 5 × /0.1 illumination lenses. 
For each illumination (left and right) a separate image was captured for each channel imaged. The fluorescent 
signal was collected using a 460–500 nm emission filter/405 nm excitation laser (Hoechst), 660/LP nm emis-
sion filter/638 nm excitation laser (AlexaFluor-647 F-actin), 575–615 nm emission filter/561 nm excitation laser 
(Cy3-αSMA) and 505–545 emission filter/488 nm excitation laser (AlexaFluor-488 cytokeratin). Α Z stack of 
∼1000 frames at 30 ms exposure on two CMOS (PCOEdge) cameras with 1920 × 1920 pixels images (2.329 μm 
pixel size and 4 μm optical sectioning steps) and lightsheet thickness ~ 10 μm was used. Zen software (Carl Zeiss; 
Germany) was used to combine the left and right illumination images at each Z-plane. Further data process-
ing, rendering of Z-stacks and visualisation in 3D was performed using Imaris software (Andor Technology; 
Switzerland).
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